Avadel Pharmaceuticals plc (AVDL)
NASDAQ: AVDL · Real-Time Price · USD
18.96
+0.06 (0.32%)
Nov 5, 2025, 4:00 PM EST - Market closed
Avadel Pharmaceuticals Stock Forecast
Stock Price Forecast
The 8 analysts that cover Avadel Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $17.56, which forecasts a -7.38% decrease in the stock price over the next year. The lowest target is $12 and the highest is $21.
Price Target: $17.56 (-7.38%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Avadel Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 1 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 8 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy → Hold Downgrades $20 | Strong Buy → Hold | Downgrades | $20 | +5.49% | Oct 28, 2025 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $19 | Buy → Hold | Downgrades | $19 | -2.43% | Oct 23, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $36 → $20 | Strong Buy → Hold | Downgrades | $36 → $20 | +5.49% | Oct 23, 2025 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $22 → $20 | Strong Buy → Hold | Downgrades | $22 → $20 | +5.49% | Oct 22, 2025 |
| Needham | Needham | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Oct 22, 2025 |
Financial Forecast
Revenue This Year
277.71M
from 169.12M
Increased by 64.21%
Revenue Next Year
363.25M
from 277.71M
Increased by 30.80%
EPS This Year
0.23
from -0.51
EPS Next Year
0.77
from 0.23
Increased by 239.17%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 288.6M | 397.2M | |||
| Avg | 277.7M | 363.3M | |||
| Low | 261.7M | 327.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 70.7% | 43.0% | |||
| Avg | 64.2% | 30.8% | |||
| Low | 54.7% | 17.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.36 | 1.20 | |||
| Avg | 0.23 | 0.77 | |||
| Low | 0.17 | 0.48 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 424.5% | |||
| Avg | - | 239.2% | |||
| Low | - | 110.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.